abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

abrdn Life Sciences Investors (NYSE:HQL) was the recipient of a large growth in short interest in August. As of August 14th, there was short interest totaling 58,626 shares, a growth of 217.9% from the July 30th total of 18,442 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 149,213 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HQL. Wedbush Securities Inc. boosted its stake in abrdn Life Sciences Investors by 50.6% during the 2nd quarter. Wedbush Securities Inc. now owns 15,960 shares of the company’s stock worth $319,000 after purchasing an additional 5,360 shares during the last quarter. KPP Advisory Services LLC boosted its position in abrdn Life Sciences Investors by 2.7% during the second quarter. KPP Advisory Services LLC now owns 25,251 shares of the company’s stock worth $505,000 after acquiring an additional 660 shares during the last quarter. 180 Wealth Advisors LLC boosted its position in abrdn Life Sciences Investors by 2.2% during the second quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock worth $3,058,000 after acquiring an additional 3,271 shares during the last quarter. NewEdge Advisors LLC boosted its position in abrdn Life Sciences Investors by 17.6% during the first quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock worth $387,000 after acquiring an additional 3,562 shares during the last quarter. Finally, WNY Asset Management LLC purchased a new stake in abrdn Life Sciences Investors during the 1st quarter valued at about $239,000. 32.21% of the stock is owned by institutional investors and hedge funds.

abrdn Life Sciences Investors Price Performance

NYSE:HQL traded up $0.01 during trading hours on Thursday, hitting $21.55. 92,299 shares of the stock were exchanged, compared to its average volume of 129,278. The firm’s fifty day moving average price is $20.14 and its 200 day moving average price is $18.16. abrdn Life Sciences Investors has a 52-week low of $13.82 and a 52-week high of $22.67.

abrdn Life Sciences Investors Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Monday, August 24th will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 11.5%. The ex-dividend date is Monday, August 24th.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.